Biotechnology company Enveric Biosciences (NASDAQ: ENVB) said it is prioritizing the development of EB-003, a compound designed to treat mental health disorders without hallucinogenic effects. The company said EB-003 is intended to promote neuroplasticity while avoiding the hallucinations associated with some psychedelic-based treatments. Enveric is advancing pre-clinical development and aims for a pre-IND meeting with the FDA in early 2025, the company announced Tuesday.
